Tight Glycemic Control in Critically Ill Children. 2017

Michael S D Agus, and David Wypij, and Eliotte L Hirshberg, and Vijay Srinivasan, and E Vincent Faustino, and Peter M Luckett, and Jamin L Alexander, and Lisa A Asaro, and Martha A Q Curley, and Garry M Steil, and Vinay M Nadkarni, and
From the Division of Medicine Critical Care (M.S.D.A., J.L.A., G.M.S.) and the Department of Cardiology (D.W., L.A.A.), Boston Children's Hospital and Harvard Medical School, Boston; the Division of Pediatric Critical Care, University of Utah Medical School, Primary Children's Hospital, Salt Lake City, and Intermountain Medical Center, Murray - both in Utah (E.L.H.); Children's Hospital of Philadelphia (V.S., V.M.N.) and the Perelman School of Medicine (V.S., M.A.Q.C., V.M.N.) and the School of Nursing (M.A.Q.C.), University of Pennsylvania - all in Philadelphia; Yale School of Medicine, New Haven, CT (E.V.F.); and Children's Medical Center Dallas and the University of Texas Southwestern Medical School, Dallas (P.M.L.).

In multicenter studies, tight glycemic control targeting a normal blood glucose level has not been shown to improve outcomes in critically ill adults or children after cardiac surgery. Studies involving critically ill children who have not undergone cardiac surgery are lacking. In a 35-center trial, we randomly assigned critically ill children with confirmed hyperglycemia (excluding patients who had undergone cardiac surgery) to one of two ranges of glycemic control: 80 to 110 mg per deciliter (4.4 to 6.1 mmol per liter; lower-target group) or 150 to 180 mg per deciliter (8.3 to 10.0 mmol per liter; higher-target group). Clinicians were guided by continuous glucose monitoring and explicit methods for insulin adjustment. The primary outcome was the number of intensive care unit (ICU)-free days to day 28. The trial was stopped early, on the recommendation of the data and safety monitoring board, owing to a low likelihood of benefit and evidence of the possibility of harm. Of 713 patients, 360 were randomly assigned to the lower-target group and 353 to the higher-target group. In the intention-to-treat analysis, the median number of ICU-free days did not differ significantly between the lower-target group and the higher-target group (19.4 days [interquartile range {IQR}, 0 to 24.2] and 19.4 days [IQR, 6.7 to 23.9], respectively; P=0.58). In per-protocol analyses, the median time-weighted average glucose level was significantly lower in the lower-target group (109 mg per deciliter [IQR, 102 to 118]; 6.1 mmol per liter [IQR, 5.7 to 6.6]) than in the higher-target group (123 mg per deciliter [IQR, 108 to 142]; 6.8 mmol per liter [IQR, 6.0 to 7.9]; P<0.001). Patients in the lower-target group also had higher rates of health care-associated infections than those in the higher-target group (12 of 349 patients [3.4%] vs. 4 of 349 [1.1%], P=0.04), as well as higher rates of severe hypoglycemia, defined as a blood glucose level below 40 mg per deciliter (2.2 mmol per liter) (18 patients [5.2%] vs. 7 [2.0%], P=0.03). No significant differences were observed in mortality, severity of organ dysfunction, or the number of ventilator-free days. Critically ill children with hyperglycemia did not benefit from tight glycemic control targeted to a blood glucose level of 80 to 110 mg per deciliter, as compared with a level of 150 to 180 mg per deciliter. (Funded by the National Heart, Lung, and Blood Institute and others; HALF-PINT ClinicalTrials.gov number, NCT01565941 .).

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007902 Length of Stay The period of confinement of a patient to a hospital or other health facility. Hospital Stay,Hospital Stays,Stay Length,Stay Lengths,Stay, Hospital,Stays, Hospital
D008297 Male Males
D011184 Postoperative Period The period following a surgical operation. Period, Postoperative,Periods, Postoperative,Postoperative Periods
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children

Related Publications

Michael S D Agus, and David Wypij, and Eliotte L Hirshberg, and Vijay Srinivasan, and E Vincent Faustino, and Peter M Luckett, and Jamin L Alexander, and Lisa A Asaro, and Martha A Q Curley, and Garry M Steil, and Vinay M Nadkarni, and
March 2020, The Journal of pediatrics,
Michael S D Agus, and David Wypij, and Eliotte L Hirshberg, and Vijay Srinivasan, and E Vincent Faustino, and Peter M Luckett, and Jamin L Alexander, and Lisa A Asaro, and Martha A Q Curley, and Garry M Steil, and Vinay M Nadkarni, and
June 2017, The New England journal of medicine,
Michael S D Agus, and David Wypij, and Eliotte L Hirshberg, and Vijay Srinivasan, and E Vincent Faustino, and Peter M Luckett, and Jamin L Alexander, and Lisa A Asaro, and Martha A Q Curley, and Garry M Steil, and Vinay M Nadkarni, and
August 2008, JAMA,
Michael S D Agus, and David Wypij, and Eliotte L Hirshberg, and Vijay Srinivasan, and E Vincent Faustino, and Peter M Luckett, and Jamin L Alexander, and Lisa A Asaro, and Martha A Q Curley, and Garry M Steil, and Vinay M Nadkarni, and
May 2010, JAMA,
Michael S D Agus, and David Wypij, and Eliotte L Hirshberg, and Vijay Srinivasan, and E Vincent Faustino, and Peter M Luckett, and Jamin L Alexander, and Lisa A Asaro, and Martha A Q Curley, and Garry M Steil, and Vinay M Nadkarni, and
July 2017, The Journal of pediatrics,
Michael S D Agus, and David Wypij, and Eliotte L Hirshberg, and Vijay Srinivasan, and E Vincent Faustino, and Peter M Luckett, and Jamin L Alexander, and Lisa A Asaro, and Martha A Q Curley, and Garry M Steil, and Vinay M Nadkarni, and
January 2010, Annales francaises d'anesthesie et de reanimation,
Michael S D Agus, and David Wypij, and Eliotte L Hirshberg, and Vijay Srinivasan, and E Vincent Faustino, and Peter M Luckett, and Jamin L Alexander, and Lisa A Asaro, and Martha A Q Curley, and Garry M Steil, and Vinay M Nadkarni, and
September 2013, Mayo Clinic proceedings,
Michael S D Agus, and David Wypij, and Eliotte L Hirshberg, and Vijay Srinivasan, and E Vincent Faustino, and Peter M Luckett, and Jamin L Alexander, and Lisa A Asaro, and Martha A Q Curley, and Garry M Steil, and Vinay M Nadkarni, and
April 2014, Nature reviews. Endocrinology,
Michael S D Agus, and David Wypij, and Eliotte L Hirshberg, and Vijay Srinivasan, and E Vincent Faustino, and Peter M Luckett, and Jamin L Alexander, and Lisa A Asaro, and Martha A Q Curley, and Garry M Steil, and Vinay M Nadkarni, and
September 2015, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies,
Michael S D Agus, and David Wypij, and Eliotte L Hirshberg, and Vijay Srinivasan, and E Vincent Faustino, and Peter M Luckett, and Jamin L Alexander, and Lisa A Asaro, and Martha A Q Curley, and Garry M Steil, and Vinay M Nadkarni, and
February 2012, World journal of critical care medicine,
Copied contents to your clipboard!